Dear Debra of America and the EB community,

It is with great pleasure that we announce the US Food and Drug Administration approval of Filsuvez® (birch triterpenes) topical gel, a new treatment for Epidermolysis Bullosa ("EB"). FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional EB in adult and pediatric patients 6 months of age and older.

This approval is an important milestone in providing a new treatment for EB and would not have been possible without debra of America's dedication, commitment, and participation in the clinical trial recruitment efforts. On behalf of Chiesi Global Rare Diseases*, I want to also express our heartfelt gratitude to you for your steadfast interactions with the FDA on behalf of the EB community and for playing such an important role in making this regulatory approval a reality.

We reached this important milestone thanks to you, and the partnership that we have built with debra of America over many years. We fully recognize and applaud the advocacy that you and debra of America have led and continued with many different groups including Health Care Professionals, legislators on Capitol Hill and with the FDA, particularly in your constant striving to ensure that the EB patient voice is represented in the regulatory process. Your efforts have significantly contributed to the approval of new treatments for EB in the US. We are honored to be a partner with debra of America and the EB community and hope to continue this successful relationship into the future.

We invite you, the EB Community, to watch a short video featuring Brett Kopelan, Executive Director, debra of America; Stuart Siedman, Global Head of Patient Advocacy, and myself. In the video, we discuss the importance of this approval and our ongoing commitment to the EB community. You can access the video through the link https://bit.ly/3trYZss or QR code provided below.

Thanks once again to you, debra of America, the patient community, as well as to healthcare providers and the patient advocacy community, for your ongoing support and collaboration. Together, we can work to build a brighter future for everyone affected by EB.

Warm regards,

Giacomo Chiesi
Chiesi Global Rare Diseases

Watch the video

*Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A in April 2023